Navigation Links
VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results
Date:2/28/2011

A issued the CRL to communicate its decision that the NDA could not be approved in its present form.  The CRL included the following areas: clinical, labeling, REMS, safety update, and drug scheduling.  We held a meeting with the FDA on January 19, 2011, to discuss the items contained in the CRL.  At this meeting the FDA requested that we assess the feasibility of performing a retrospective observational study utilizing existing healthcare databases to review fetal outcomes in the offspring of women who received 100mg of topiramate for migraine prophylaxis during pregnancy. In the QNEXA studies, which included 15 births from women exposed to topiramate, there were no reports of any adverse fetal outcomes.

We expect to reach agreement with the FDA, and if deemed feasible, initiate the retrospective observational study on fetal outcomes within the next two months.  We will provide more details as soon as an agreement is reached.  It is our goal to resubmit the NDA for QNEXA by the end of 2011.

Although no other requests for additional information or studies were made by the FDA at the meeting, there can be no assurances that the FDA will not request or require us to provide additional information or undertake additional studies in connection with the QNEXA NDA.  

"In 2010, we also made significant progress with the development of QNEXA as a treatment for obesity by filing for approval in the European Union, and for avanafil we completed the pivotal phase 3 studies," stated Leland Wilson, chief executive officer of VIVUS. "We are working diligently on responding to the FDA's request to assess the feasibility of conducting a retrospective observational study. Our goals for 2011 include the continued advancement towards approval of QNEXA in the US and the EU and filing the NDA for avanafil."

Fourth Quarter ResultsIn November 2010, we sold MUSE and the related assets.  Accordingly, all historical financial
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
2. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
3. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
4. VIVUS Announces Promotion of Peter Tam to President
5. VIVUS to Present at Lazard Capital Markets Healthcare Conference
6. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
7. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
8. VIVUS Announces Sale of MUSE Assets to Meda
9. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
10. VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
11. VIVUS to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014   Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... scheduled to present at the Biotech Showcase™ 2015 taking ... on January 12-14, 2015. Michael ... Creek Pharmaceuticals, will present preclinical and clinical data for ... anti-inflammatory pharmacological characteristics. Dr. Mullan will outline the Company,s ...
(Date:11/21/2014)... , 21. November 2014 ... heute bekannt gegeben, dass die Europäische ... die Kennzeichnung als Orphan-Medizinprodukt an Palovarotene ... Unternehmens zur Behandlung von Fibrodysplasia ossificans ... stark beeinträchtigende genetische Krankheit, die von ...
(Date:11/21/2014)... N.J. , Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... Krakauer , Chief Executive Officer, will be presenting at the ... New York Palace Hotel in New York ... 2014 at 2:00 PM ET. In addition, Mr. Krakauer and ... available for separate one-on-one meetings during the day. ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 3Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 4Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3
... March 17, 2011 A recently issued patent ... award winning and best selling medical thermometer brand, ... recently been granted U.S. Patent No. 7,787,938, entitled, ... and Trademark Office, adding to the already extensive ...
... VEGAS, March 17, 2011 A new study by Craig ... and North Cypress Medical Center in Houston, presented this week ... the improved photon sensitivity of new detector technologies such as ... dose patient receive from BSGI/MBI studies by 75%.  However, low ...
Cached Medicine Technology:Exergen Granted New Patent for Temporal Artery Thermometers 2New Technologies Open the Door for Low Dose Breast-Specific Gamma Imaging (BSGI) / Molecular Breast Imaging (MBI) 2
(Date:11/22/2014)... November 22, 2014 Recently, UWDress.com is ... wedding guest dresses . In addition, the company has ... , As a leading online supplier of wedding ... beautiful outfits. The unusual best wedding guest gowns are ... the amazing designs, this new selection is famous for ...
(Date:11/22/2014)... Calif. (PRWEB) November 22, 2014 ... applications was announced today which safely detects and ... high frequency radio waves. Developed by RHT SpectraSafe, ... and hosts broad applications in other areas including ... to security. , Using high frequency radio waves ...
(Date:11/22/2014)... A Xarelto lawsuit has been filed on behalf ... million in damages from the makers and marketers of the ... the woman began using Xarelto in March 2012 and used ... she suffered life-threatening bleeding in July 2012 and as a ... emotional distress. The lawsuit purports that the woman’s injuries are ...
(Date:11/22/2014)... HealthDay Reporter FRIDAY, Nov. 21, ... are treated in an ambulance by a neurologist equipped with ... The sooner patients get the clot dissolver -- tissue plasminogen ... the researchers noted. For the best outcome, the drug needs ... start, the researchers said. "The so-called ,golden hour, is ...
(Date:11/21/2014)... November 21, 2014 Porcelain veneer ... smiles for patients in preparation for the coming holiday ... fronts of teeth, look completely natural, and can be ... veneers are also valued for their ability to strengthen ... can be used on one or several teeth to ...
Breaking Medicine News(10 mins):Health News:Best Wedding Guest dresses Introduced by UWDress.com 2Health News:RHT SpectraSafe announces a Radical New Airport Security Technology that Is More Effective, Less Invasive 2Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 2Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 3Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 4Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 3Health News:Los Angeles Porcelain Veneers Dentist, Dr. Kevin Sands, Now Creates Picture-Perfect Smiles for Patients for the Holiday Season 2
... Inc. (Nasdaq: LMAT ) announced today that it ... 30, 2008, after the close of the,market. In conjunction ... same day at 5:00 PM ET. The call will ... listen to the live webcast at, http://www.lemaitre.com/investor, or ...
... 18 Dr. James B.,Peake, the Secretary of ... open a unique vocational counseling center for disabled,veterans., ... this center is yet,another partnership that recognizes the ... and access to resources to veterans sets,the stage ...
... BlueCross BlueShield of South,Carolina today announced that Greenville businesswoman ... A native of Elberton, Ga., Shaw now lives ... Corp., a family investment corporation.,She previously worked for C ... National,Bank of South Carolina, and Manly Investment Group in ...
... destination for quality skincare,will debut three new locations ... SEATTLE, April 18 Calidora Skin Clinic, ... its doors,in Southern California this April. The three ... Monica - will offer Southern Californians the,chance to ...
... been proved, one expert says , , FRIDAY, April 18 (HealthDay ... severe psoriasis appears to be safe and effective, a Canadian ... which is a calcineurin inhibitor, significantly improve symptoms of psoriasis. ... is the first oral medication in 20 years to show ...
... (OTC,Bulletin Board: CHRX, CHRXU, CHRXW), a leading provider of ... has,changed to CHRX from PMQC. The Company,s common stock ... About Chem Rx Corporation, Founded more than ... of institutional pharmacy services in the New York City,metropolitan ...
Cached Medicine News:Health News:Disabled Counseling Center Comes to Twin Cities 2Health News:Shaw Elected to S.C. BlueCross BlueShield Board 2Health News:Upscale Seattle-Based Skincare Clinic Expands Into California With Unique Custom Tailored Skincare Approach 2Health News:New Psoriasis Pill Appears Effective 2Health News:New Psoriasis Pill Appears Effective 3Health News:Chem Rx Corporation Changes Ticker Symbol to CHRX 2
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
... The 5mm AEM Laparoscopic Instruments incorporate ... AEM Instruments are shielded and monitored to ... of the instrument caused by insulation failure ... risk. The protective shield built into all ...
Medicine Products: